1. 5-HT1A receptor stimulation in the medial prefrontal cortex mediates the antidepressant effects of mGlu2/3 receptor antagonist in mice. (15th July 2018) Authors: Fukumoto, Kenichi; Iijima, Michihiko; Funakoshi, Takeo; Chaki, Shigeyuki Journal: Neuropharmacology Issue: Volume 137(2018) Page Start: 96 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system. (1st February 2023) Authors: Chaki, Shigeyuki; Watanabe, Mai Journal: Neuropharmacology Issue: Volume 223(2023) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Depression-resistant Phenotype in Mice Overexpressing Regulator of G Protein Signaling 8 (RGS8). (15th July 2018) Authors: Kobayashi, Yuki; Takemoto, Risa; Yamato, Shogo; Okada, Tomoya; Iijima, Michihiko; Uematsu, Yoshikatsu; Chaki, Shigeyuki; Saito, Yumiko Journal: Neuroscience Issue: Volume 383(2018) Page Start: 160 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study. (September 2020) Authors: Kamiya, Makoto; Sabia, Helene D.; Marella, Julie; Fava, Maurizio; Nemeroff, Charles B.; Umeuchi, Hideo; Iijima, Michihiko; Chaki, Shigeyuki; Nishino, Izumi Journal: Journal of psychiatric research Issue: Volume 128(2020) Page Start: 43 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Is the History Repeated? Can (2R, 6R)-Hydroxynorketamine be Another Antidepressant?. (December 2018) Authors: Chaki, Shigeyuki; Yamaguchi, Jun-ichi Journal: Journal of experimental neuroscience Issue: Volume 12(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Ketamine and its metabolites: Potential as novel treatments for depression. (1st June 2023) Authors: Hashimoto, Kenji; Chaki, Shigeyuki Journal: Neuropharmacology Issue: Volume 230(2023) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. MGlu receptors as potential targets for novel antidepressants. (February 2018) Authors: Chaki, Shigeyuki; Fukumoto, Kenichi Journal: Current opinion in pharmacology Issue: Volume 38(2018) Page Start: 24 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. MGlu2/3 Receptor Antagonists as Novel Antidepressants. (June 2017) Authors: Chaki, Shigeyuki Journal: Trends in pharmacological sciences Issue: Volume 38:Number 6(2017) Page Start: 569 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Safety and pharmacokinetic profiles of MGS0274 besylate (TS‐134), a novel metabotropic glutamate 2/3 receptor agonist prodrug, in healthy subjects. Issue 11 (10th June 2020) Authors: Watanabe, Mai; Marcy, Brian; Kinoshita, Kohnosuke; Fukasawa, Misako; Hikichi, Hirohiko; Chaki, Shigeyuki; Okuyama, Shigeru; Gevorkyan, Hakop; Yoshida, Shigeru Journal: British journal of clinical pharmacology Issue: Volume 86:Issue 11(2020) Page Start: 2286 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Targeting of Metabotropic Glutamate Receptors for the Development of Novel Antidepressants. (April 2019) Authors: Chaki, Shigeyuki; Koike, Hiroyuki; Fukumoto, Kenichi Journal: Chronic stress Issue: Volume 3(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗